Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty Drugsmedical mutual - ohio inflammatory conditions Prio…
    Ask Trek AI about this page
    Currentmedical mutual - ohioPolicy N/A

    Inflammatory Conditions Care Value Policy

    Customize your policy alerts

    Sign up for all medical mutual - ohio policy alerts

    Know when medical mutual - ohio releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Medical Mutual of Ohio's coverage and prior authorization expectations for multiple biologic and oral therapies used to treat inflammatory conditions (e.g., RA, PsA, psoriasis, IBD). Applies to providers seeking PA for the listed drugs under this payer.

    Policy Summary
    Payermedical mutual - ohio
    PolicyInflammatory Conditions Care Value Policy
    Policy CodePolicy N/A
    Change TypeAdministrative — no material clinical changes
    Effective DateMay 21, 2026
    Last ReviewMay 21, 2026
    Next Review DateMay 21, 2026
    Key ActionObtain prior authorization and document required prior therapy trials or claims verification (90–120 days within a 130-day lookback) for continuation approvals.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    multipletherapy classes listed
    1 yrstandard continuation length
    130 daysclaims lookback
    90 or 120 daysrequired prior duration
    6 monthstypical initial approval

    Coverage Criteria by Drug and Indication

    General coverage criteria

    Covered when ALL of the following are met:

    General program requirements: Patient meets the respective standard Prior Authorization Policy criteria for the requested agent; AND when clinically appropriate the patient has trialed Preferred Product(s) per the policy step table; AND for continuation of Non-Preferred subcutaneous or oral products the request includes verification of prior use either by prescription claims history showing 90 or 120 days of use within a 130-day lookback OR prescriber verification when claims history is unavailable (paid-use only; no samples/coupons).see documentation and lookback rules

    Approvals for continuation are typically for 1 year; initial approvals are time-limited per agent (commonly 3–6 months).

    Cimzia — Rheumatoid Arthritis Initial Therapy (example)

    Approve for 6 months when BOTH criteria are met

    Cimzia RA initial: i. Patient meets the standard Inflammatory Conditions - Cimzia Prior Authorization Policy criteria; AND ii. Patient has tried TWO of the following (documentation required): a tocilizumab subcutaneous product (examples Actemra SC, Tyenne SC), Enbrel, an adalimumab product, Rinvoq, or Xeljanz/XR. A trial of multiple products of the same named product family (e.g., multiple adalimumab products or multiple tocilizumab products) counts as ONE product; either or both Xeljanz formulations collectively count as ONE product.two prior products

    Approval duration: 6 months.

    Cimzia — Ankylosing Spondylitis Initial Therapy

    Approve for 6 months when BOTH criteria are met

    Cimzia AS initial: i. Patient meets the standard Inflammatory Conditions - Cimzia Prior Authorization Policy criteria; AND ii. Patient has tried TWO of Enbrel, an adalimumab product, Rinvoq, Taltz, or Xeljanz/XR (documentation required). Multiple products of the same molecule (e.g., multiple adalimumab products) count as one trial; Xeljanz formulations count collectively as one.two prior products

    Approval duration: 6 months.

    Cimzia — Juvenile Idiopathic Arthritis Initial Therapy

    Approve for 6 months when BOTH criteria are met

    Cimzia JIA initial: i. Patient meets the standard Inflammatory Conditions - Cimzia Prior Authorization Policy criteria; AND ii. Patient has tried TWO of a tocilizumab subcutaneous product, Enbrel, an adalimumab product, Rinvoq/Rinvoq LQ, or Xeljanz (documentation required). Trials of multiple products within the same product family count as one trial; certain IV formulations (e.g., Actemra IV, infliximab) may count where specified.two prior products

    Approval duration: 6 months.

    Cimzia — Psoriatic Arthritis Initial Therapy

    Approve for 6 months when BOTH criteria are met

    Cimzia PsA initial: i. Patient meets the standard Inflammatory Conditions - Cimzia Prior Authorization Policy criteria; AND ii. Patient has tried TWO of Enbrel, an adalimumab product, Otezla/Otezla XR, Skyrizi SC, Sotyktu, an ustekinumab SC product, Taltz, Tremfya SC, Rinvoq/Rinvoq LQ, or Xeljanz/XR (documentation required). Multiple products from the same molecule family count collectively as a single trial where noted.two prior products

    Approval duration: 6 months.

    Cimzia — Plaque Psoriasis Initial Therapy

    Approve for 3 months when BOTH criteria are met

    Cimzia plaque psoriasis initial: i. Patient meets the standard Inflammatory Conditions - Cimzia Prior Authorization Policy criteria; AND ii. Patient has tried TWO of Enbrel, an adalimumab product, Icotyde, Otezla/Otezla XR, Skyrizi SC, Sotyktu, an ustekinumab SC product, Taltz, or Tremfya SC (documentation required). Trials of multiple products in the same family count as one trial where specified.two prior products

    Approval duration: 3 months.

    Plaque Psoriasis - Initial Therapy

    Approve for 3 months if BOTH conditions are met:

    Plaque Psoriasis initial Cimzia: (i) Patient meets the standard Inflammatory Conditions - Cimzia Prior Authorization Policy criteria; AND (ii) Patient has tried TWO of Enbrel, an adalimumab product, Icotyde, Otezla, Otezla XR, Skyrizi SC, Sotyktu, an ustekinumab SC product, Taltz, or Tremfya SC (documentation required).two prior agents

    Multiple products of same molecule count as one; examples of adalimumab/ustekinumab products are provided in policy.

    Crohn's Disease - Initial Therapy

    Approve for 6 months if BOTH conditions are met:

    Crohn's initial Cimzia: (i) Patient meets the standard Inflammatory Conditions - Cimzia Prior Authorization Policy criteria; AND (ii) Patient has tried ONE of an adalimumab product, Omvoh subcutaneous, Skyrizi subcutaneous (on-body injector), an ustekinumab subcutaneous product, Tremfya subcutaneous, or Zymfentra (documentation required). Certain IV biologic trials (e.g., infliximab, Entyvio, ustekinumab IV) may also count where noted.one prior agent

    Approval duration: 6 months.

    Continuation Therapy - Patients currently receiving Cimzia

    Approve for 1 year if BOTH criteria are met:

    Continuation on Cimzia: (i) Patient meets the standard Inflammatory Conditions - Cimzia Prior Authorization Policy criteria; AND (ii) Patient meets the indication-specific prior-therapy conditions enumerated for the diagnosis (examples: RA — tried two of tocilizumab SC, Enbrel, an adalimumab product, Rinvoq, or Xeljanz/XR; AS — tried two of Enbrel, an adalimumab product, Rinvoq, Taltz, or Xeljanz/XR; Crohn's — tried one listed agent OR has been established on Cimzia ≥90 days with claims verification). Verification via claims (≥90-day supply within past 130 days) or prescriber attestation required when claims unavailable.varies by indication

    Detailed subclauses a–g list per-indication prior therapy requirements; approval duration: 1 year.

    Simponi Subcutaneous - Initial and continuation therapy (partial)

    Approve for 6 months for listed indications if BOTH conditions are met:

    Simponi Subcutaneous initial therapy: (i) Patient meets the standard Inflammatory Conditions - Simponi Subcutaneous Prior Authorization Policy criteria; AND (ii) Patient has trialed the number and list of prior agents required for the indication (commonly TWO agents such as Enbrel, adalimumab products, Taltz, Rinvoq, or Xeljanz/XR) with documentation required. Trials of multiple products within the same product family count as one product where specified.typically two prior agents

    If prior-trial requirement not met, offer review for Step 1/Step 2 preferred products listed in policy.

    Ulcerative Colitis - Initial Therapy

    Approve for 6 months if BOTH conditions are met:

    Ulcerative Colitis initial Simponi: (i) Patient meets the standard Inflammatory Conditions - Simponi Subcutaneous Prior Authorization Policy criteria; AND (ii) Patient is <18 years OR (if ≥18) has tried ONE of an adalimumab product, Omvoh SC, Skyrizi SC (on-body injector), an ustekinumab SC product, Tremfya SC, Velsipity, or Zymfentra (documentation required). Certain IV biologic trials may count per policy notes.one prior agent for adults; age-based exception for pediatrics

    Preferred product review offered if criterion not met.

    Other Conditions / All Conditions

    Approve when the patient meets the respective standard product PA criteria:

    Other conditions: For other or unspecified conditions, approve Cimzia, Enbrel, or listed adalimumab products if the patient meets the respective standard Inflammatory Conditions prior authorization policy criteria. Initial durations are per the referenced PA policy; continuation approvals are typically for 1 year when continuation verification criteria are met.varies by product/indication

    Refer to the specific product PA policy for dosing and duration.

    Ankylosing Spondylitis — product-specific trial requirements (examples shown)

    Approve if patient meets standard product prior authorization criteria AND meets the indication-specific trial requirements:

    AS product-specific trial example: Patient meets the standard Inflammatory Conditions PA criteria for the requested product; AND patient has tried TWO of Enbrel, an adalimumab product, Rinvoq, Taltz, or Xeljanz/XR (documentation required). Trials of multiple products within the same family count as one trial where specified.two prior products

    Applies as an example of product-specific trial requirements.

    Psoriatic Arthritis — product-specific trial requirements (examples shown)

    Approve if patient meets standard product prior authorization criteria AND the following trial requirements:

    Psoriatic Arthritis product-specific example: Patient meets the standard Inflammatory Conditions PA criteria for the requested product; AND patient has tried TWO of Enbrel, an adalimumab product, Otezla/Otezla XR, Rinvoq/Rinvoq LQ, Skyrizi SC, Sotyktu, an ustekinumab SC product, Taltz, Tremfya SC, or Xeljanz/XR (documentation required). Multiple products from the same molecule family count as a single trial per policy notes.two prior products

    Documentation required; counting rules apply.

    Ulcerative Colitis — age-stratified criteria (example)

    Approve if patient meets the standard product prior authorization criteria AND meets age-specific rules:

    Ulcerative Colitis - age-stratified: (a) Patient <18 years with Ulcerative Colitis: Approve when standard PA criteria met; OR (b) Patient ≥18 years with Ulcerative Colitis: Approve when standard PA criteria met AND patient has tried ONE of an adalimumab product, Omvoh SC, Skyrizi SC (on-body injector), an ustekinumab SC product, Tremfya SC, Velsipity, or Zymfentra (documentation required).age-dependent

    Certain IV therapies may count toward prior trials as noted.

    Simponi subcutaneous — continuity and initiation criteria

    Approve per standard Simponi PA criteria when meeting one of several continuity/initiation pathways:

    Established on Simponi Aria: Prescriber attests patient has been established on Simponi Aria for at least 90 days.>=90 days

    Prescriber verification acceptable when claims history unavailable.

    Established on Simponi subcutaneous: Patient has been established on Simponi subcutaneous ≥90 days AND prescription claims indicate at least a 90-day supply was dispensed within the past 130 days (or prescriber verification if claims unavailable).>=90 days and 130-day lookback

    Claims verification required where specified.

    Tocilizumab (Actemra/Tyenne) / Kevzara — indication-specific initial therapy

    Approve initial therapy for specified indications if both the referenced standard PA criteria are met and additional trial or comorbidity criteria apply:

    Tocilizumab (Actemra/Tyenne) - RA initial: Patient meets the standard tocilizumab subcutaneous Prior Authorization Policy criteria; AND either patient has tried one adalimumab product OR prescriber documents heart failure or previously treated lymphoproliferative disorder.varies

    Approval duration: typically 6 months.

    Kevzara - RA initial: Patient meets the standard Kevzara Prior Authorization Policy criteria; AND patient has tried TWO of tocilizumab SC, Enbrel, an adalimumab product, Rinvoq/Rinvoq LQ, or Xeljanz OR prescriber documents qualifying comorbidity (heart failure or prior lymphoproliferative disorder).two prior products or comorbidity

    Documentation required where noted.

    Continuation therapy for tocilizumab or Kevzara

    Approve for 1 year when the patient is currently receiving the agent and meets standard PA criteria plus one of the continuity conditions:

    Tocilizumab/Kevzara continuation: Patient meets standard tocilizumab or Kevzara PA criteria AND meets at least one continuity condition: qualifying prior-trial history per indication, prescriber-reported qualifying comorbidity, established IV use ≥90 days, or established SC use ≥90 days with claims showing ≥90-day supply within past 130 days (or prescriber verification if claims unavailable).>=90 days where applicable

    Approval duration: 1 year.

    Bimzelx — Ankylosing Spondylitis and Hidradenitis Suppurativa

    Approve for indication-specific durations when standard Bimzelx PA criteria and trial requirements are met:

    Bimzelx AS initial: Patient meets the standard Bimzelx Prior Authorization Policy criteria; AND patient has tried ONE of Enbrel, an adalimumab product, or Taltz (documentation required).one prior agent

    Approval duration: 6 months for AS.

    Bimzelx HS initial: Patient meets the standard Bimzelx Prior Authorization Policy criteria for hidradenitis suppurativa; AND patient has tried ONE of an adalimumab product or Cosentyx SC (documentation required).one prior agent

    Approval duration: 3 months for HS.

    Initial Therapy - Ankylosing Spondylitis

    Bimzelx — Ankylosing Spondylitis initial therapy

    Ankylosing Spondylitis initial approval (Bimzelx): Approve for 6 months if BOTH: (i) patient meets the standard Inflammatory Conditions - Bimzelx PA criteria; AND (ii) patient has tried one of Enbrel, an adalimumab product, or Taltz (documentation required).6 months

    Examples of acceptable adalimumab products are listed in the policy.

    Initial Therapy - Hidradenitis Suppurativa

    Bimzelx — Hidradenitis Suppurativa initial therapy

    Hidradenitis Suppurativa initial approval (Bimzelx): Approve for 3 months if BOTH: (i) patient meets the standard Inflammatory Conditions - Bimzelx PA criteria for hidradenitis suppurativa; AND (ii) patient has tried ONE of an adalimumab product or Cosentyx subcutaneous (documentation required).3 months

    Examples of acceptable adalimumab products are listed.

    Initial Therapy - nr-axSpA

    Bimzelx — Non-radiographic spondyloarthritis (nr-axSpA) initial therapy

    nr-axSpA initial approval (Bimzelx): Approve for 6 months if BOTH: (i) patient meets the standard Inflammatory Conditions - Bimzelx PA criteria; AND (ii) patient has tried one of Cimzia or Taltz (documentation required). Alternative trials (Enbrel, adalimumab product, infliximab product, Simponi, Cosentyx) may also count per policy notes.6 months

    If criterion not met, offer review for Preferred Product lists.

    Initial Therapy - Plaque Psoriasis

    Bimzelx — Plaque Psoriasis initial therapy

    Plaque Psoriasis initial approval (Bimzelx): Approve for 3 months if BOTH: (i) patient meets the standard Inflammatory Conditions - Bimzelx PA criteria for plaque psoriasis; AND (ii) patient has tried ONE of Enbrel, an adalimumab product, Icotyde, Otezla/XR, Skyrizi SC, Sotyktu, an ustekinumab SC product, Taltz, or Tremfya SC (documentation required).3 months

    Examples of acceptable adalimumab/ustekinumab products are listed.

    Initial Therapy - Psoriatic Arthritis

    Bimzelx — Psoriatic Arthritis initial therapy

    Psoriatic Arthritis initial approval (Bimzelx): Approve for 6 months if BOTH: (i) patient meets the standard Inflammatory Conditions - Bimzelx PA criteria; AND (ii) patient has tried ONE of Enbrel, an adalimumab product, Otezla/XR, Skyrizi SC, Sotyktu, an ustekinumab SC product, Taltz, or Tremfya SC (documentation required). Other agents (Cimzia, infliximab products, Simponi, Cosentyx) may also count per policy notes.6 months

    Documentation required where indicated.

    Continuation Therapy - Bimzelx

    Bimzelx — Continuation (patients currently receiving Bimzelx)

    Continuation approval (Bimzelx): Approve for 1 year if (i) patient meets the standard Inflammatory Conditions - Bimzelx PA criteria; AND (ii) patient meets ONE of the condition-specific prior-trial lists for their indication OR has been established on Bimzelx ≥90 days with prescription claims showing a 90-day supply dispensed within the past 130 days (or prescriber verification if claims unavailable).1 year

    Claims verification or prescriber attestation required when claims are incomplete.

    Initial Therapy - Cosentyx Subcutaneous

    Cosentyx (subcutaneous) — Initial therapy and indication-specific rules

    Cosentyx AS initial: Approve for 6 months if BOTH: (i) patient meets the standard Inflammatory Conditions - Cosentyx SC PA criteria; AND (ii) patient has tried TWO of Enbrel, an adalimumab product, Rinvoq, Taltz, or Xeljanz/XR (documentation required). Trials of certain other agents (Cimzia, infliximab products, Simponi, Bimzelx) may also count where specified.6 months

    Documentation required for prior trials.

    Cosentyx nr-axSpA initial: Approve for 6 months if BOTH: (i) patient meets standard Cosentyx SC PA criteria; AND (ii) patient has tried TWO of Cimzia, Taltz, or Rinvoq (documentation required).6 months

    Alternate trials may count as specified.

    Cosentyx plaque psoriasis initial: Approve for 3 months if BOTH: (i) patient meets standard Cosentyx SC PA criteria; AND (ii) patient has tried TWO of Enbrel, an adalimumab product, Icotyde, Otezla/XR, Skyrizi SC, Sotyktu, an ustekinumab SC product, Taltz, or Tremfya SC (documentation required).3 months

    Multiple-product trials of same class may count as one where noted.

    Cosentyx PsA initial: Approve for 6 months if BOTH: (i) patient meets standard Cosentyx SC PA criteria; AND (ii) patient meets age-based prior trial requirements (≥18: two trials; <18: one trial) with documentation as specified.6 months

    Age distinctions and acceptable prior agents listed in policy.

    Continuation Therapy - Cosentyx

    Cosentyx — Continuation for patients currently receiving Cosentyx (SC or IV)

    Continuation approval (Cosentyx): Approve for 1 year if (i) patient meets the standard Inflammatory Conditions - Cosentyx PA criteria; AND (ii) patient meets one of the condition-specific prior-trial or established-therapy conditions (e.g., ankylosing spondylitis: tried TWO of Enbrel, an adalimumab product, Rinvoq, Taltz, or Xeljanz/XR). Documentation of prior trials or claims verification of established therapy required as specified.1 year

    Claims verification (≥90-day supply within past 130 days) or prescriber attestation permitted when claims unavailable.

    Other Conditions

    Other Conditions

    Other conditions - Bimzelx: Approve Bimzelx (initial therapy for a duration as directed or 1 year for continuing therapy) if patient meets the standard Inflammatory Conditions - Bimzelx Prior Authorization Policy criteria for indications not explicitly enumerated in the prior lists.varies

    Catch-all for other indications.

    Cosentyx - Current therapy and alternative pathways

    Cosentyx (secukinumab) approvals under Care Value when patient is currently receiving therapy or for initial therapy in specified indications

    Current Cosentyx approval (5A): Approve for 1 year if patient meets the standard Inflammatory Conditions - Cosentyx SC PA criteria AND meets ONE of the listed prior-therapy/established-therapy conditions for the indication (a–g), e.g., ankylosing spondylitis: tried TWO of Enbrel, an adalimumab product, Rinvoq, Taltz, or Xeljanz/XR; or established on Cosentyx SC ≥90 days with claims verification.1 year

    Conditions a–g enumerate acceptable prior trials or established-use verification.

    Alternate review (5B): If patient meets standard Cosentyx PA criteria but not the Care Value additional condition, offer review for specified Preferred Products using their respective standard PA criteria (lists differ by indication).NA

    Preferred alternatives listed in policy.

    Siliq / Ilumya / Icotyde - Plaque psoriasis

    Product-specific Care Value requirements for plaque psoriasis (initial therapy and patients currently receiving product).

    Siliq/Ilumya/Icotyde plaque psoriasis initial: Approve for 3 months if patient meets the standard product PA criteria AND has tried TWO of Enbrel, an adalimumab product, Icotyde, Otezla/Otezla XR, Skyrizi SC, Sotyktu, an ustekinumab SC product, Taltz, or Tremfya SC (documentation required). Multiple products of the same family count as one trial where specified.3 months

    Documentation required for prior trials.

    Siliq/Ilumya/Icotyde continuing: Approve for 1 year if patient meets the standard product PA criteria AND either meets the two-product prior-trial requirement OR has been established on the product ≥90 days with claims showing a 90-day supply within the past 130 days (or prescriber verification).1 year

    Offer preferred-product review if Care Value condition not met.

    Entyvio SC - Crohn's disease

    Entyvio subcutaneous approval criteria for Crohn's disease.

    Entyvio SC Initial (Crohn's): Approve for 6 months if (i) patient meets the standard Inflammatory Conditions - Entyvio Subcutaneous PA criteria; AND (ii) patient has tried TWO of an adalimumab product, Omvoh SC, Skyrizi SC, Tremfya SC, an ustekinumab SC product, Zymfentra, Cimzia, or Rinvoq (documentation required), OR (per prescriber) is undergoing or has started Entyvio IV induction. Trials of multiple adalimumab products count as one where specified.6 months

    Documentation required for prior agents; IV induction counts as alternative pathway.

    Entyvio SC Alternate review: If patient meets standard Entyvio SC PA criteria but not Care Value additional condition, offer review for Step 1/Step 2a products listed in policy per their standard PA criteria.NA

    Preferred alternatives listed by indication.

    Other biologics and IL-blockers - general

    Many listed biologics and small molecules are approved when the patient meets the respective standard product-specific Inflammatory Conditions prior authorization policy criteria; Care Value sections add prior-trial requirements or continuity rules.

    Other biologics/IL-blockers general: Approve initial therapy (duration as directed) or continuing therapy (typically 1 year) for listed biologics when patient meets the referenced standard product-specific prior authorization policy criteria. For certain products or indications Care Value requires prior trials of specified alternatives for initial approval or verification of established therapy for continuation approvals.varies by product

    See product-specific nodes for details (Entyvio, Cosentyx, Siliq, Ilumya, etc.).

    Entyvio Subcutaneous - Ulcerative Colitis Initial Therapy

    Approve for 6 months if ALL of the following are met:

    Entyvio SC UC initial: i. Patient meets the standard Inflammatory Conditions - Entyvio Subcutaneous PA criteria; AND ii. Patient has either tried TWO of listed alternatives (adalimumab products, Skyrizi SC, an ustekinumab SC product, Zymfentra, Omvoh SC, Rinvoq, Simponi SC, Tremfya SC, Velsipity, or Xeljanz/XR) with documentation OR (per prescriber) is undergoing Entyvio IV induction. Multiple products of same family count as a single trial where specified.6 months

    Documentation required for prior trials; IV induction counts as pathway.

    Entyvio Subcutaneous - Crohn's Disease / Continuing Therapy

    Approve for 1 year if ALL of the following are met:

    Entyvio SC continuation (CD/UC): i. Patient meets the standard Inflammatory Conditions - Entyvio Subcutaneous PA criteria; AND ii. Patient meets ONE of: (a) Crohn's — tried TWO of listed alternatives (adalimumab products, Omvoh SC, Skyrizi SC, Tremfya SC, ustekinumab SC, Zymfentra, Cimzia, Rinvoq) with documentation; OR (b) Ulcerative colitis — tried TWO of listed alternatives with documentation; OR (c) established on Entyvio IV ≥90 days per prescriber; OR (d) established on Entyvio SC ≥90 days with claims showing ≥90-day supply within past 130 days (or prescriber verification if claims unavailable).1 year

    Claims verification may be waived with prescriber attestation if claims unavailable.

    Entyvio Subcutaneous - Other Conditions

    Approve Entyvio subcutaneous for initial therapy (duration as directed) or 1 year for continuing therapy if:

    Entyvio SC other conditions: Patient meets the standard Inflammatory Conditions - Entyvio Subcutaneous Prior Authorization Policy criteria for the indicated condition (other indications per product PA).varies

    Refer to Entyvio SC PA policy for dosing and additional criteria.

    Kineret - Rheumatoid Arthritis Initial and Continuing Therapy

    Initial: Approve for 6 months; Continuing: Approve for 1 year when criteria met.

    Kineret RA initial: i. Patient meets standard Inflammatory Conditions - Kineret PA criteria; AND ii. Patient has tried TWO of a tocilizumab SC product, Enbrel, an adalimumab product, Rinvoq, or Xeljanz/XR (documentation required).two prior products

    Initial duration: 6 months; continuation requires prior trials or establishment on therapy with claims verification per policy.

    Kineret continuation: i. Patient meets standard Kineret PA criteria; AND ii. Patient meets ONE of: has tried TWO of listed alternatives OR established on Kineret ≥90 days with claims showing ≥90-day supply within past 130 days or prescriber verification.

    Continuation duration: 1 year.

    Orencia Subcutaneous - Rheumatoid Arthritis, JIA/JRA, Psoriatic Arthritis Initial and Continuing Therapy

    Initial: Approve for 6 months; Continuing: approve for 1 year when criteria met.

    Orencia RA/JIA initial: i. Patient meets the standard Inflammatory Conditions - Orencia Subcutaneous PA criteria; AND ii. Patient has tried TWO of tocilizumab SC, Enbrel, an adalimumab product, Rinvoq, or Xeljanz/XR (documentation required) OR prescriber documents qualifying comorbidity (heart failure, prior lymphoproliferative disorder, prior serious infection, or demyelinating disorder).two prior products or prescriber-documented contraindication

    Initial duration: 6 months.

    Orencia continuation: i. Patient meets standard Orencia PA criteria; AND ii. Patient meets ONE of listed continuation conditions including prior trials OR established IV/SC use ≥90 days with claims showing ≥90-day supply within past 130 days (or prescriber verification).

    Continuation duration: 1 year.

    Psoriatic Arthritis - Initial Therapy

    Approve for 6 months if the patient meets BOTH of the following:

    Psoriatic Arthritis initial (Orencia): i. Patient meets the standard Inflammatory Conditions - Orencia Subcutaneous PA criteria; AND ii. Patient meets ONE of: (a) ≥18 years and has tried TWO of Enbrel, an adalimumab product, Otezla/Otezla XR, Rinvoq/Rinvoq LQ, Skyrizi SC, Sotyktu, an ustekinumab SC product, Taltz, Tremfya SC, or Xeljanz/XR (documentation required); OR (b) <18 years and has tried ONE of specified agents; OR (c) prescriber documents qualifying comorbidity (heart failure, prior lymphoproliferative disorder, prior serious infection, or demyelinating disorder).

    Initial duration: 6 months.

    Rheumatoid Arthritis / Juvenile Idiopathic Arthritis / Psoriatic Arthritis - Currently Receiving Orencia

    Approve for 1 year if the patient meets BOTH of the following:

    Orencia continuation examples: i. Patient meets the standard Inflammatory Conditions - Orencia PA criteria; AND ii. Patient meets ONE of the continuation conditions such as prior trials for RA/JIA/PSA OR established IV/SC use ≥90 days with claims showing ≥90-day supply within past 130 days (or prescriber verification).

    Continuation duration: 1 year.

    Olumiant (baricitinib) - Rheumatoid Arthritis initial and continuation

    Initial: Approve for 6 months when BOTH met; Continuation: Approve for 1 year when BOTH met.

    Olumiant initial and continuation: Initial: patient meets standard Inflammatory Conditions - Olumiant PA criteria AND has tried TWO of tocilizumab SC, Enbrel, an adalimumab product, Rinvoq, or Xeljanz/XR (documentation required) — approve 6 months. Continuation: meet standard PA criteria and either prior trials or established use ≥90 days with claims verification (or prescriber attestation) — approve 1 year.two prior products / 90-day verification

    Documentation required where specified.

    Rinvoq / Rinvoq LQ - Multiple indications (Ankylosing spondylitis, Crohn's, JIA, nr-axSpA, RA)

    Initial approvals generally for 6 months when BOTH of the following are met:

    Rinvoq general initial: i. Patient meets the standard Inflammatory Conditions - Rinvoq/LQ Prior Authorization Policy criteria; AND ii. Patient meets the indication-specific prior therapy requirement (examples: Crohn's — tried one adalimumab product; JIA — tried Enbrel or an adalimumab product; nr-axSpA — tried Cimzia; RA — tried Enbrel or an adalimumab product). Trials of multiple products of same family count as one where specified.6 months typical

    If step criterion not met, offer review of Preferred/Step products per policy.

    Non-Radiographic Spondyloarthritis (nr-axSpA) & Rheumatoid Arthritis - Initial Therapy

    Approve for 6 months if BOTH criteria met:

    nr-axSpA initial (Rinvoq): i. Patient meets the standard Inflammatory Conditions - Rinvoq/LQ PA criteria; AND ii. Patient has tried Cimzia (a trial of Enbrel, an adalimumab product, an infliximab product, or Simponi also counts).

    Approval duration: 6 months.

    RA initial (Rinvoq): i. Patient meets the standard Inflammatory Conditions - Rinvoq/LQ PA criteria; AND ii. Patient has tried one of Enbrel or an adalimumab product (trial of Cimzia, infliximab, or Simponi also counts).

    Approval duration: 6 months.

    nr-axSpA - Initial Therapy

    Approve for 6 months if ALL of the following are met:

    nr-axSpA initial therapy (Rinvoq): i. Patient meets the standard Inflammatory Conditions - Rinvoq/LQ PA criteria; AND ii. Patient has tried Cimzia (alternatively Enbrel, an adalimumab product, an infliximab product, or Simponi may count).

    Approval duration: 6 months.

    Rheumatoid Arthritis - Initial Therapy

    Approve for 6 months if ALL of the following are met:

    RA initial therapy (Rinvoq): i. Patient meets the standard Inflammatory Conditions - Rinvoq/LQ PA criteria; AND ii. Patient has tried one of Enbrel or an adalimumab product (a trial of Cimzia, an infliximab product, or Simponi also counts).

    Approval duration: 6 months.

    Psoriatic Arthritis - Initial Therapy

    Approve for 6 months if ALL of the following are met:

    PsA initial therapy (Rinvoq): i. Patient meets the standard Inflammatory Conditions - Rinvoq/LQ PA criteria; AND ii. Patient has tried ONE of Enbrel or an adalimumab product (a trial of Cimzia, an infliximab product, or Simponi also counts). If not met, offer review for listed Preferred Products.

    Approval duration: 6 months.

    Ulcerative Colitis - Initial Therapy

    Approve for 6 months if ALL of the following are met:

    UC initial therapy (Rinvoq): i. Patient meets the standard Inflammatory Conditions - Rinvoq/LQ PA criteria; AND ii. Patient has tried ONE adalimumab product (a trial of an infliximab product or Simponi SC also counts).

    Approval duration: 6 months; preferred alternatives offered if not met.

    Continuation Therapy - Patients Currently Receiving Rinvoq/Rinvoq LQ

    Approve for 1 year if ALL of the following are met:

    Continuation on Rinvoq: i. Patient meets the standard Inflammatory Conditions - Rinvoq/LQ PA criteria; AND ii. Patient meets ONE of multiple indication-specific conditions (e.g., prior trial of specified biologic(s) for the indication OR has been established on Rinvoq ≥90 days with verification of at least a 90-day supply dispensed within the past 130 days or prescriber verification).>=90 days therapy and >=90-day supply within past 130 days

    If criteria not met, offer review for listed alternative products per indication.

    Juvenile Idiopathic Arthritis - Initial and Continuation Therapy

    Initial: Approve for 6 months if ALL met; Continuation: Approve for 1 year if ALL met

    JIA initial (Rinvoq): i. Patient meets the standard Inflammatory Conditions - Rinvoq/LQ (or Xeljanz/XR as applicable) PA criteria; AND ii. Patient has tried one of Enbrel or an adalimumab product (documentation required).

    Approval duration: 6 months for initial; continuation pathways include established use verification.

    JIA continuation (Rinvoq): i. Patient meets the standard PA criteria; AND ii. Patient has tried Enbrel or an adalimumab product OR has been established on Rinvoq/LQ ≥90 days with verification via claims showing ≥90-day supply within past 130 days (or prescriber attestation).

    Continuation duration: 1 year.

    Xeljanz/XR and other product-specific initial therapy rules

    For indications listed, approve for 6 months if ALL of the following are met:

    Xeljanz/XR initial examples: i. Patient meets the standard Inflammatory Conditions - Xeljanz/XR PA criteria; AND ii. Patient has tried one of Enbrel or an adalimumab product (a trial of Cimzia, an infliximab product, or Simponi also counts) as required per indication. If step criterion not met, offer review for Preferred Products listed.

    Approval duration: 6 months typical for initial therapy.

    All Other Conditions

    Approve Rinvoq/Rinvoq LQ for initial therapy or 1 year for continuation if the patient meets:

    Other conditions (Rinvoq): Patient meets the standard Inflammatory Conditions - Rinvoq/LQ Prior Authorization Policy criteria (initial duration as directed; continuation typically 1 year when continuation verification met).

    Refer to product-specific PA policy for details.

    Psoriatic Arthritis - Initial Therapy

    Approve for 6 months if BOTH conditions are met:

    Psoriatic Arthritis initial (Xeljanz): i. Patient meets the standard Inflammatory Conditions - Xeljanz/XR PA criteria; AND ii. Patient has tried ONE of Enbrel or an adalimumab product (examples listed). Trials of Cimzia, an infliximab product, or Simponi also count where specified.

    Approval duration: 6 months.

    Ulcerative Colitis - Initial Therapy

    Approve for 6 months if BOTH conditions are met:

    Ulcerative Colitis initial (Xeljanz): i. Patient meets the standard Inflammatory Conditions - Xeljanz/XR PA criteria; AND ii. Patient has tried ONE adalimumab product (examples listed). A trial of an infliximab product or Simponi subcutaneous also counts where specified.

    Approval duration: 6 months.

    Continuation - Currently Receiving Xeljanz/XR (Ankylosing Spondylitis, RA, JIA, PsA, UC)

    Approve for 1 year if BOTH conditions are met:

    Continuation on Xeljanz/XR: i. Patient meets the standard Inflammatory Conditions - Xeljanz/XR PA criteria; AND ii. Patient meets an indication-specific condition such as prior trial of Enbrel or an adalimumab product for the indication OR has been established on Xeljanz/XR ≥90 days with claims showing a 90-day supply within past 130 days (or prescriber verification if claims unavailable).>=90 days

    Continuation duration: 1 year.

    Juvenile Idiopathic Arthritis - Initial Therapy

    Approve for 6 months if BOTH conditions are met:

    JIA initial (Xeljanz): i. Patient meets the standard Inflammatory Conditions - Xeljanz/XR PA criteria; AND ii. Patient has tried one of Enbrel or an adalimumab product (documentation required). If step requirement not met, offer review for Preferred Products listed.

    Approval duration: 6 months.

    Step-down / Alternative product review

    If the required prior biologic/step criterion is not met:

    Offer alternative/step review: Offer to review for specified Step 1 or Preferred Products (examples include Enbrel, multiple adalimumab biosimilars/brands, Simlandi, Otezla/Otezla XR, Skyrizi SC, Sotyktu, Ilumya/Imuldosa, Selarsdi, ustekinumab-ttwe, Yesintek, Taltz, Tremfya, Velsipity, Zymfentra, Omvoh, etc.) using their respective standard Inflammatory Conditions Prior Authorization Policy criteria.

    Product lists are indication-specific in the policy.

    Other conditions and product-specific PA

    Approve when standard product-specific PA criteria are met:

    Other products and conditions: Approve Xeljanz oral solution, Otezla/Otezla XR, Velsipity, Zeposia, Sotyktu, and other named products if the patient meets the standard PA criteria for that specific product/policy. Durations per referenced PA policies (initial as directed; continuation commonly 1 year).varies by product

    Refer to the specific product PA policy referenced in this document.

    Agent-indication approval matrix

    Agent-indication approval flags (√ = approved; -- = not approved) reflect which agents are approved for each targeted indication:

    Agent-indication approval matrix: Approval mappings are provided by table: a checkmark (√) indicates the agent is approved for that indication and a dash (--) indicates the agent is not approved or not listed for that indication. Tables cover TNFis, IL-17/23/12-23 agents, oral tsDMARDs, and other biologics — use the tables to determine agent-specific indication approvals.

    See Table 1–4 in policy for per-agent, per-indication flags and notes (e.g., some IL-17 agents not approved for Crohn's/UC).

    For Non-Preferred products, the policy directs reviewers to the relevant product-specific Care Value policies for details on National Preferred and Basic Formularies and any program-specific requirements. The document explicitly references the Inflammatory Conditions - Adalimumab Products Care Value Policy and the Inflammatory Conditions - Ustekinumab Subcutaneous Products Care Value Policy as the primary cross-references for Non‑Preferred adalimumab and ustekinumab agents, and notes that prescribers must supply written documentation supporting trials of Preferred Products when indicated (e.g., chart notes, prescription claims, receipts including patient identifiers).

    When a requested Non‑Preferred product falls under a Care Value pathway, the reviewer must follow the referenced standard Inflammatory Conditions prior authorization policy for that agent and indication. The policy repeatedly instructs that for Non‑Preferred adalimumab or ustekinumab products the reviewer should refer to the respective Inflammatory Conditions Care Value policies (e.g., Adalimumab Products Care Value; Ustekinumab Subcutaneous Products Care Value) for step requirements, preferred alternatives, and documentation expectations.

    The policy does not list broad absolute exclusions in the excerpted sections. Instead, coverage is conditioned on meeting the referenced standard prior authorization criteria and any indication‑specific prior‑therapy or establishment requirements. Where the Care Value condition is not met, the policy directs offering review for preferred or step products rather than stating the agent is categorically excluded.

    Across the Care Value sections shown, there are no explicit unconditional exclusions; instead the policy prescribes alternative preferred or step products to be offered if the Care Value additional criteria are unmet. For example, Bimzelx and Cosentyx pathways instruct offering review for named Preferred/Step products when the required prior trials or continuity criteria are not satisfied.

    Coverage is explicitly conditioned on prior authorization (PA) and on meeting the referenced standard prior authorization policy criteria for each product and indication. In addition, many Care Value approvals require documented prior therapy trials (step therapy) or, for continuation of Non‑Preferred subcutaneous or oral products, verification of prior use via claims or prescriber attestation (see verification rules for 90 or 120 days of use within a 130‑day lookback).

    If a patient does not meet the Care Value additional criteria for the requested Non‑Preferred product, the reviewer should offer to review for specified Preferred/Step products per the policy. The policy provides indication‑specific alternative lists (Step 1/Step 2a products) and directs use of the respective standard Inflammatory Conditions PA criteria when conducting that alternate review.

    There are no additional exclusions beyond failure to meet the listed criteria in the provided excerpts. Where an agent is not listed as approved for a particular indication in the tabular mapping (absence of a checkmark or a dash), that denotes the agent is not approved for that indication under this policy matrix; otherwise, agents are governed by the same PA, step, and continuation criteria described.

    When Care Value criteria are not met, the policy consistently requires offering review of Preferred or Step products and documents the expectation that prescribers provide supporting documentation for prior trials. Examples of alternatives are provided per indication (e.g., Enbrel, named adalimumab biosimilars, Cimzia, Simponi, Skyrizi, Taltz, Xeljanz/XR), and reviewers should use the referenced standard PA policies to evaluate those alternatives.

    The excerpt does not contain additional standalone exclusionary language beyond the conditional rules already described. Instead, the policy emphasizes that requests failing to meet the referenced standard PA criteria or required prior‑therapy/continuation verification will be ineligible under the Care Value pathway and should be redirected to review for listed preferred alternatives or denied per the standard PA policy.

    Some implied exclusions arise from the tabular agent‑to‑indication mappings: Table 1 and subsequent tables use approval flags (√) and dashes (--) to indicate which agents are approved for each targeted indication. A dash (--) in these tables indicates the agent is not approved for that specific indication under this policy matrix, and reviewers should follow the table when determining whether an agent is an acceptable choice for the requested indication.

    The policy tables explicitly mark multiple agents as not approved for particular indications (represented as ‘--’). These indication‑specific not‑approved flags are part of the agent‑indication approval matrix and reflect the policy’s mapping of which drug classes (e.g., many IL‑17 agents) are appropriate for each specialty area. Reviewers should consult the table for the definitive approval status by agent and indication.

    The provided excerpts do not include explicit language using the phrase “not medically necessary”. Instead, the policy denotes non‑approval for specific agent‑indication pairs via the table flags (a dash indicates not approved for that indication). Requests that do not meet the referenced standard PA criteria, step requirements, or continuation verification may be denied under the regular PA process rather than by a global ‘not medically necessary’ statement in these excerpts.

    Coding and Claims Verification

    NDC identifier cited in policyNDC
    NDCs starting with 82009Identifies specific adalimumab-ryvk NDC range used in preferred product lists
    Referenced NDCsNDC
    NDCs starting with 82009adalimumab-ryvk specific NDC prefix referenced for preferred products
    Referenced product identifiersNDC
    NDCs starting with 82009Identifier referenced for adalimumab-ryvk product
    Notable NDC notationNDC
    NDCs starting with 82009adalimumab-ryvk (specific NDC prefix noted)
    Referenced NDC prefixNDC
    NDCs starting with 82009adalimumab-ryvk specific NDC prefix listed as preferred/step product
    NDC prefix referencedNDC
    82009NDCs starting with 82009 referenced for adalimumab-ryvk
    Prescription claims lookback (130 days)
    Lookback period for prescription claims verification130 days
    Required duration on Non-Preferred product for continuation (90 or 120 days within a 130-day lookback)
    Required duration on Non-Preferred product for continuation90 or 120 days within a 130-day lookback
    Claims history lookback (130 days)
    Claims history lookback window130 days
    Required prior use duration for continuation verification (90 or 120 days within 130-day lookback)
    Prior use duration required for continuation verification90 or 120 days within a 130-day lookback (verified by claims or prescriber if claims unavailable)
    established on Cimzia duration (>=90 days and 90-day supply within 130 days)
    Established-on Cimzia minimum durationAt least 90 days
    Claims verification requirementAt least a 90-day supply dispensed within the past 130 days [verification in prescription claims history required]
    Prescriber verification alternativeIf 130 days of claims history unavailable, prescriber must verify ≥90 days of paid use (no samples/coupons)
    Prescription claims lookback (130 days)
    Prescription claims lookback130 days
    Establishment on therapy duration (>= 90 days)
    Established-on therapy duration>= 90 days
    Claims lookback window130 days (used to verify a 90-day supply dispensed within past 130 days)
    Prescriber verification optionIf claims unavailable, prescriber attestation may be accepted
    Continuation verification window (90-day supply within past 130 days or prescriber verification)
    Continuation verification windowAt least a 90-day supply dispensed within the past 130 days (or prescriber verification if claims unavailable)
    Claims-history requirement130-day lookback to document the 90-day supply
    established-therapy verification lookback (90-day supply within past 130 days)
    Established-therapy verification lookback90-day supply dispensed within past 130 days
    Claims or prescriber verificationIf claims history unavailable, prescriber verification required
    Established therapy verification window (90-day supply within past 130 days or prescriber verification)
    Established therapy verification windowAt least a 90-day supply dispensed within the past 130 days (or prescriber verification if claims unavailable)
    Applies to continued approvalsUsed to document established use for continuation approvals (typically 1 year)
    Prior Rinvoq dispensing verification (>=90-day supply within past 130 days)
    Prior Rinvoq dispensing verification≥90-day supply dispensed within the past 130 days [verification in prescription claims history required]
    Prescriber verification alternativeIf claims unavailable, prescriber must verify ≥90 days of paid use
    Established therapy verification window for Xeljanz/XR (>=90 days with 90-day supply within past 130 days or prescriber verification)
    Xeljanz/XR established therapy verification>= 90 days of Xeljanz/XR received with at least a 90-day supply dispensed within the past 130 days (claims) or prescriber verification if claims history unavailable
    Continuation approval durationTypically approved for 1 year when verified

    Provider Required Actions, Documentation, and Denial Risks

    Prior Authorization

    Obtain PA and document preferred‑product trials

    Submit a prior authorization request and ensure the patient meets the referenced standard Inflammatory Conditions prior authorization policy; when clinically appropriate, document trials of the Preferred Product(s) per the policy table before requesting approval of a Non‑Preferred product.

    • Continuation of Non‑Preferred subcutaneous/oral products requires verification via claims or prescriber if claims unavailable (see continuation verification rules).
    • If preferred‑product trial requirement not met, the reviewer will offer review for a Preferred/Step product per the step table.
    Step Therapy

    Meet standard PA and step‑therapy rules

    All requests must meet the respective standard Prior Authorization Policy criteria and indicate any required step‑therapy trials per the policy table; if step requirements are unmet, the requestor should be offered review for the listed Step/Preferred products.

    • Non‑Preferred approvals are often directed to one or more Step 1 (Preferred) or Step 2 products.
    • Some Step 3 Non‑Preferred agents require documentation of trials of two Step 1 or 2a products.
    Prior Authorization

    PA approvals are time‑limited (initial and continuation)

    Authorization approvals are time‑limited: initial approvals are commonly 3 or 6 months (varies by agent/indication) and continuation approvals are typically for 1 year when standard PA and any indication‑specific continuity requirements are met.

    • Examples: Cimzia plaque psoriasis initial approval = 3 months (when criteria met).
    • Cimzia initial approvals for many indications = 6 months; continuation approvals (patients currently receiving) = 1 year.
    Documentation Required

    Verify established‑on‑therapy (often ≥90 days) for continuation

    For continuation approvals based on being established on therapy, verify the patient has been on therapy for the required period (often ≥90 days) and provide claims or prescriber verification per the policy to support a 1‑year renewal.

    • Example: Simponi continuation — established ≥90 days and claims show a 90‑day supply within the past 130 days or prescriber verification.
    • If claims history (130 days) is unavailable, prescriber must verify at least 90 days of paid use (no samples/coupons).
    Prior Authorization

    Care Value approvals conditional on meeting PA and step criteria

    Care Value approvals are conditional: the reviewer must confirm standard PA criteria plus any Care Value additional prior‑therapy or establishment requirements for the product/indication before granting the specified approval duration.

    • If Care Value additional conditions are not met, offer review for specified Preferred/Step products per the standard PA policies.
    • Durations vary by product and indication (e.g., initial 3–6 months; continuation typically 1 year).
    Note

    Follow the referenced standard PA policy for each drug

    Follow the referenced standard Prior Authorization Policies for each agent; the Care Value document cross‑references product‑specific PA policies (e.g., Tocilizumab SC policy) that must be satisfied in the request.

    • Refer to the Inflammatory Conditions – [product] Prior Authorization Policy for agent‑specific clinical criteria.
    • Prescribers must provide any documentation the referenced PA policy requires.
    Prior Authorization

    Document meeting standard PA criteria and prior trials

    Requests must include documentation that the patient meets the referenced 'standard Inflammatory Conditions' prior authorization policy criteria and any specified prior‑therapy trials; initial approvals commonly issued for 6 months and continuation for 1 year when requirements are documented.

    • Examples: Rinvoq/Xeljanz initial approvals often 6 months when standard PA and trial requirements met; continuation approvals generally 1 year.
    • Document prior trials as noted (number and acceptable agents vary by indication).
    Prior Authorization

    PA is required and must cite standard PA criteria

    Prior authorization is required for initial and continuation therapy and the request must document meeting the referenced standard PA criteria; provide required prior‑therapy documentation as noted in each product section.

    • Initial Rinvoq approvals: patient must meet the Rinvoq/LQ PA criteria and the indication‑specific prior therapy requirement.
    • If prior therapy trial requirement is not met, offer review for listed Preferred Products.
    Prior Authorization

    Rinvoq initial PA: meet Rinvoq/LQ PA + prior‑therapy rule

    For initial Rinvoq therapy, confirm the patient meets the standard Rinvoq/LQ prior authorization criteria and the indication‑specific prior therapy requirement (e.g., specified biologic trial) before requesting a 6‑month initial approval.

    • Example: nr‑axSpA initial Rinvoq requires prior trial of Cimzia (or specified alternatives).
    • If prior trial not met, offer review for Preferred Product (Cimzia or Taltz).
    Prior Authorization

    Rinvoq continuation PA: verify prior use or prior biologic trial

    For patients currently receiving Rinvoq/Rinvoq LQ, request prior authorization for continuation by confirming standard Rinvoq/LQ PA criteria and one of the indication‑specific continuity conditions (including prior biologic trial or verification of ≥90 days Rinvoq use with claims), to qualify for a 1‑year approval.

    • Continuation verification: ≥90 days on Rinvoq and claim history showing a 90‑day supply within past 130 days, or prescriber verification if claims unavailable.
    • If continuity conditions unmet, offer review for specified Preferred alternatives.
    Prior Authorization

    Xeljanz/XR initial PA: meet Xeljanz PA + prior biologic trial

    For initial Xeljanz/XR requests, document that the patient meets the standard Xeljanz/XR PA criteria and has tried the specified alternative biologic (often Enbrel or an adalimumab product) per the indication to receive a 6‑month initial approval.

    • Example: Psoriatic arthritis initial Xeljanz/XR requires trial of Enbrel or an adalimumab product.
    • If step criterion not met, offer review for Step 1 Preferred products.
    Prior Authorization

    Xeljanz/XR continuation PA: verify prior use or prior biologic trial

    For continuation of Xeljanz/XR, provide documentation that the patient meets the standard PA criteria and the indication‑specific condition (e.g., prior biologic trial or established Xeljanz/XR use with claims or prescriber verification) to obtain a 1‑year approval.

    • Established use verification: ≥90 days on Xeljanz/XR and claims showing a 90‑day supply within past 130 days, or prescriber attestation if claims unavailable.
    • If not met, offer review for Preferred alternatives per step table.
    Prior Authorization

    Sotyktu: follow standard Sotyktu PA for initial and continuation

    Sotyktu approvals require meeting the standard Sotyktu Prior Authorization Policy criteria for the indication (initial per that PA policy or 1 year for continuation); include required documentation and step‑therapy information when applicable.

    • If Care Value additional conditions are not met for requested product, offer review for specified Preferred/Step products per the standard PA policies.
    Step Therapy

    Trial Preferred product(s) per step table before Non‑Preferred

    This program requires trials of Preferred Product(s) (Step 1) per the policy table before approval of Non‑Preferred Products, when clinically appropriate; document trials as required by the step table.

    • A trial of more than one adalimumab product counts as one Preferred Product trial where noted.
    • Exceptions and situations allowing Non‑Preferred trials are described in product‑specific criteria.
    Step Therapy

    Step therapy structure: Step 1 before Non‑Preferred steps

    Step structure: require Step 1 (Preferred) trials before advancing to Non‑Preferred (Step 2a/2b/3a/3b); many Non‑Preferred approvals are directed to one Step 1 product or require documented trials of two Step 1/2a products for some Step 3 approvals.

    • Some indications specifically direct Non‑Preferred agents to a single Step 1 product (see step table).
    • Step 3a Non‑Preferred often requires documentation of trials of TWO Step 1 or 2a products.
    Step Therapy

    Offer review for Preferred/Step products when trials undocumented

    If required prior therapy trials are not documented, the policy requires offering review for the listed Preferred/Step products for that indication using the respective standard PA criteria.

    • Examples: For Cimzia plaque psoriasis, if two prior agents are not documented, offer review for Preferred products including Enbrel and listed adalimumab products.
    • For Simponi indications, offer Step 1/Step 2a product review when prior trials are unmet.
    Step Therapy

    Offer alternative Preferred/Step products when criteria unmet

    If the patient has not met the specific trial requirements, the reviewer should offer to review for preferred or step‑product alternatives listed for the indication using their standard PA criteria.

    • Example: Entyvio SC initial — if prior‑therapy condition not met, offer review for Step 1 or Step 2a products (adalimumab biosimilars, Omvoh SC, Skyrizi SC, etc.).
    Step Therapy

    Refer to listed Preferred/Step alternatives when trials missing

    If required prior trial(s) are not met, direct the reviewer to evaluate a Preferred Product or Step product listed for the indication (specific alternatives enumerated in the policy) under the respective standard PA policy.

    • Adalimumab‑ryvk NDCs starting with 82009 are included in preferred lists; trials of multiple adalimumab products count as one where noted.
    Step Therapy

    Offer alternate Preferred/Step products if Care Value conditions fail

    When Care Value additional conditions for a requested product are not satisfied, require the reviewer to offer review for specified Preferred or Step products using their standard PA criteria as alternative options.

    • Examples: Cosentyx or Siliq Care Value sections instruct offering review for multiple Preferred products when Care Value conditions are unmet.
    Step Therapy

    Offer Step 1/2a alternatives when core criteria unmet

    If core criteria are not met for a requested product, the reviewer should offer to review for Step 1 or Step 2a products (extensive lists of biologic or targeted alternatives are provided) using their standard PA criteria.

    • Many product sections list Step 1/2a alternatives (adalimumab biosimilars, Enbrel, Skyrizi, Taltz, etc.) that may be reviewed as substitutes.
    Step Therapy

    Offer Preferred/Step alternatives when secondary criteria unmet

    If secondary or indication‑specific criteria are not met, offer review for Step 1 or Step 2a / Preferred Products (lists vary by indication) using the respective standard Inflammatory Conditions PA criteria.

    • Example: Orencia and other agents list Step 1/2a preferred alternatives when prior‑therapy rules are unmet.
    • Lists differ by indication—follow the product section for specifics.
    Step Therapy

    Prior trial of Enbrel/Cimzia/adalimumab commonly required

    Many indications require prior trial of specific preferred agents (commonly Enbrel, Cimzia, or an adalimumab product) before approval; if those trials are not documented, the request should be referred for review of a Preferred Product using standard PA criteria.

    • Example: Rinvoq and Xeljanz indications commonly require trial of Enbrel or an adalimumab product.
    • If trial requirement not met, offer review for listed Preferred alternatives.
    Step Therapy

    Offer review for Step/Preferred products when step criteria unmet

    When step criteria (e.g., prior Enbrel or adalimumab trial) are not met, the requestor must be offered review for listed Step 1 or Preferred products and the reviewer must assess those products under their standard PA policies.

    • Product lists include multiple adalimumab biosimilars and other preferred agents; document trials per the listed PA criteria when reviewing alternatives.
    Note

    Check the referenced PA policies for step sequencing details

    Refer to the selected standard Prior Authorization Policies for any agent‑ and indication‑specific step therapy sequencing or detailed step requirements.

    • The Care Value policy cross‑references product‑specific PA policies which contain detailed sequencing and clinical criteria.
    Documentation Required

    Provide written documentation of prior trials when requested

    Prescribers must provide written documentation supporting prior trials when documentation is required (chart notes, prescription claims records, prescription receipts), and include patient identifiers.

    • Documentation examples: chart notes, prescription claims, receipts.
    • All documentation must include patient‑specific identifying information.
    Documentation Required

    Types of acceptable documentation for prior trials

    Acceptable documentation includes chart notes, prescription claims records, and prescription receipts to confirm prior trials; the prescriber must supply these records when the criteria indicate [documentation required].

    • Documentation must evidence the agent trialed and dates/duration where possible.
    • If claims history is unavailable for continuation, prescriber verification attesting to paid use (no samples/coupons) is required.
    Documentation Required

    Document trials of specified prior therapies (examples provided)

    Document trials of the specific prior therapies listed in the criteria (e.g., Enbrel, adalimumab products, Rinvoq, Taltz, Xeljanz/XR, ustekinumab products); note that multiple products of the same molecule class may count collectively as a single trial per policy rules.

    • Examples: multiple adalimumab products count as ONE product for meeting trial requirements.
    • Document which exact products were used and provide supporting records when requested.
    Documentation Required

    Examples of acceptable trial documentation

    When prior‑trial documentation is requested, provide examples such as chart notes, prescription claims records, and prescription receipts to substantiate trials of the named products; note that multiple products within a molecule family may count collectively as one trial.

    • Examples listed include Enbrel, adalimumab biosimilars, Rinvoq, Taltz, Xeljanz/XR, Skyrizi, Tremfya, etc.
    • Ensure documentation aligns with the trial counting rules described in the policy.
    Documentation Required

    Verify continuation with claims history (90‑day supply within 130 days)

    For continuation requests, verify prior use via prescription claims history showing at least a 90‑day supply dispensed within the past 130 days, or provide prescriber verification when claims are unavailable, to meet established‑therapy continuation rules.

    • This verification supports a 1‑year continuation approval when other criteria are met.
    • If 130 days of claims history is unavailable, prescriber must attest to paid use and duration (no samples/coupons).
    Documentation Required

    Document prior medication trials and claims history for PA

    Provide documentation of prior trials of the specified agents (names/examples appear in the policy) and include claims history or prescriber verification to demonstrate prior dispensing when required.

    • Documentation must show agent names, dates, and evidence of trial duration where applicable.
    • If claims unavailable, prescriber attestation may be used per the policy rules.
    Documentation Required

    Verify prior Cimzia dispensing (≥90‑day supply within 130 days)

    To verify established on Cimzia for continuation, provide prescription claims history showing at least a 90‑day supply dispensed within the past 130 days, or obtain prescriber verification if claims are not available.

    • This verification supports a 1‑year continuation approval for patients currently receiving Cimzia.
    • If claims not available, prescriber must verify the patient has been receiving paid Cimzia for the required period.
    Documentation Required

    Provide claims history or prescriber attestation for established therapy

    Document prior medication trials and provide prescription claims history to verify prior dispensing (e.g., 90‑day supply within past 130 days) or prescriber attestation if claims are unavailable; include examples of acceptable agents per the product sections.

    • Examples shown across product sections (Entyvio, Orencia, Kineret, etc.) list acceptable prior agents and the documentation required.
    • Claims verification exceptions allow prescriber attestation when 130 days of claims history cannot be accessed.
    Documentation Required

    Follow trial counting rules when documenting prior trials

    Count trials per the policy's trial‑counting rules: multiple products of the same molecule class (e.g., multiple adalimumab biosimilars) count collectively as a single prior‑product trial; document trials accordingly.

    • Policy explicitly notes trials of multiple adalimumab, ustekinumab, tocilizumab, Xeljanz/Rinvoq products count as ONE product where specified.
    • Ensure documentation indicates which product family was trialed and how counting rules apply.
    Documentation Required

    Verification requirement for continuation based on prior Rinvoq dispensing

    To verify prior Rinvoq therapy for continuation approvals, provide claims history demonstrating at least a 90‑day supply dispensed within the past 130 days; if claims are not available, the prescriber must verify established paid use.

    • This verification supports a 1‑year continuation approval under the Rinvoq/LQ section.
    • Prescriber verification must attest to paid claims (no samples/coupons) when claims history is unavailable.
    Documentation Required

    Claims or prescriber verification required for Xeljanz/XR continuation

    For continuation of Xeljanz/XR, submit prescription claims history showing at least a 90‑day supply dispensed within the past 130 days; if claims are unavailable, include prescriber verification attesting to paid use and duration.

    • This evidence supports a 1‑year continuation approval when other PA criteria are met.
    • If claims history is incomplete, prescriber attestation must confirm paid dispensing and duration.
    Note

    Cite the required PA policy (Sotyktu note) when submitting

    Include the required standard product PA policy reference when submitting requests; for Sotyktu, be aware that Sotyktu approvals follow its standard Sotyktu Prior Authorization Policy and any Care Value additions.

    • Providers must follow the referenced standard PA policies for indication‑specific criteria.
    • If Care Value adds prior‑trial requirements, they must be documented in addition to the standard PA criteria.
    Denial Risk

    Risk: missing verification prevents continuation approval

    Failure to provide verification of prior use of a Non‑Preferred product (claims showing 90–120 days within a 130‑day lookback or prescriber verification when claims unavailable) may result in non‑approval of continuation requests.

    • Claims must show the specified duration within the 130‑day lookback; if not available, prescriber must verify paid use (no samples/coupons).
    Denial Risk

    Risk: lack of continuation verification may trigger denial

    If required claims history or prescriber verification for continuation of a Non‑Preferred product is lacking (i.e., failure to verify 90 or 120 days within a 130‑day lookback), the request may be denied.

    • This applies to Non‑Preferred subcutaneous and oral products seeking continuation under Care Value rules.
    • Prescriber attestation can be used only when claims history is unavailable and must confirm paid use.
    Denial Risk

    Denial risk: Cimzia plaque psoriasis without required trials

    Requests for Cimzia for plaque psoriasis will be denied if the requestor does not meet BOTH the standard Cimzia PA criteria and documentation of TWO specified prior therapies as listed for plaque psoriasis.

    • Cimzia plaque psoriasis initial requires two prior agents (examples provided) and [documentation required].
    • If 5Ai is met but 5Aii is not, reviewer should offer to review for Preferred products.
    Denial Risk

    Claims verification risk for established therapy continuation

    If prescription claims history cannot verify the required 90‑day supply within the past 130 days for continuation, the continuity criteria may not be met unless prescriber verification and paid claims evidence are provided, risking non‑approval.

    • Examples: Simponi and Bimzelx continuation sections require claim verification of a 90‑day supply within a 130‑day lookback or prescriber verification.
    • Prescriber verification must confirm paid dispensing (no samples/coupons).
    Denial Risk

    Denial risk: insufficient Bimzelx prior‑trial history

    Failure to meet both the standard Bimzelx PA criteria and the required prior biologic/trial history for the indication will render the request ineligible for approval under the Bimzelx Care Value pathway.

    • Example: Bimzelx ankylosing spondylitis initial requires trying one of Enbrel, an adalimumab product, or Taltz.
    • If criterion not met, offer review for Preferred Products per the policy.
    Denial Risk

    Denial triggers: missing prior‑therapy or established‑therapy evidence

    Failure to meet listed prior‑therapy or established‑therapy requirements (e.g., not documenting required prior trials or established use) will prevent approval under Care Value pathways and may prompt offering review for alternative preferred products.

    • Denial triggers include missing documentation of required prior agents or lack of claims verification for established therapy.
    • When Care Value criteria are unmet, the reviewer should offer Preferred/Step alternatives.
    Denial Risk

    Denial risk: prior therapy not documented

    Failure to document trials of required prior agents (for example, two adalimumab products or other specified alternatives) may result in denial of an initial therapy request for indications that list such requirements (e.g., ulcerative colitis).

    • Ensure documentation of the named prior agents and apply trial counting rules when multiple biosimilars were used.
    • If not documented, offer review for the listed Preferred products.
    Denial Risk

    Denial risk: unable to verify prior therapy for continuation

    For continuation approvals, inability to verify prior use (e.g., 90‑day prior use) via prescription claims or prescriber verification may trigger denial of the continuation request.

    • This applies across multiple agents (Entyvio, Ilumya, Siliq examples).
    • If claims history is incomplete, prescriber must attest to paid use and duration to avoid denial.
    Denial Risk

    Denial risk: missing required prior‑trial documentation

    Failure to document required prior trials of specified therapies (for example, required two prior agents for some psoriatic arthritis adult initial therapy rules) may lead to denial of the initial request.

    • Policy sections (Orencia, Cosentyx, Cimzia, etc.) require documentation of specified numbers of prior agents for initial approvals.
    • If not met, offer to review for Step 1 or Preferred products.
    Denial Risk

    Denial risk: missing 90‑day prior‑use verification for continuation

    For continuation approvals, lack of verification of a 90‑day prior use period (or inability to verify claims history within past 130 days) risks denial unless prescriber verification is provided documenting paid use.

    • Examples: Orencia, Olumiant continuation sections require claims proof of 90‑day supply within past 130 days or prescriber verification.
    • Prescriber verification must confirm paid claims (no samples/coupons).
    Denial Risk

    Denial risk: failure to meet PA and step therapy requirements

    Initial therapy requests may be denied if the patient has not met the standard product‑specific prior authorization criteria or has not trialed the specified preferred biologic(s) required by the step therapy rules (e.g., Rinvoq/LQ indications).

    • Example: Rinvoq initial approvals require meeting Rinvoq/LQ PA criteria and specified prior biologic trials; lacking those may prevent approval.
    • When unmet, offer review for Preferred alternatives.
    Denial Risk

    Denial risk: Xeljanz/XR initial requests without required trials

    Initial Xeljanz/XR requests will be denied if the patient does not meet the standard Xeljanz/XR PA criteria and has not tried required alternative biologic(s) (e.g., Enbrel or an adalimumab product) specified for the indication.

    • Example: Xeljanz/XR psoriatic arthritis and ulcerative colitis initial rules require trial of Enbrel or an adalimumab product; lacking this triggers denial.
    • If unmet, offer review for Preferred products per the step table.
    Denial Risk

    Denial risk: non‑adherence to referenced standard PA criteria

    Requests that do not meet the selected standard Prior Authorization Policy criteria for the specific patient population may be denied; ensure the submitted request adheres to the referenced standard PA policy for that agent and indication.

    • Cross‑reference the product‑specific PA policy cited in the Care Value document before submission.
    • Provide all required documentation and claims verification as described to reduce denial risk.

    Step Therapy Tables and Preferred Product Pathways

    Policy requirementSummary / action
    Trial(s) of Preferred Product(s) required prior to Non-Preferred Products when clinically appropriatePatient must meet the respective standard Prior Authorization Policy criteria AND, when clinically appropriate, trial the Preferred Product(s) listed in the step table before approval of Non-Preferred products.
    Continuation verification for Non-Preferred subcutaneous or oral productsFor continuation, verification is required: either claims history showing 90 or 120 days of use within a 130-day lookback OR prescriber verification if 130 days of claims history unavailable.
    Step table instructionImplication for approvals
    Follow step table per indication (Step 1, Step 2a/2b, Step 3a/3b)Non-Preferred approvals are directed to one or more Step 1 or 2a products as specified by indication; some Step 3 non-preferred require documentation of trials of two Step 1 or 2a products.
    Interpretation of Step 2/3 rulesWhen a Non-Preferred product is in Step 2a/2b/3, the request must demonstrate trials of the indicated Step 1/2 alternatives (or provide required documentation for two prior Step 1/2a products for Step 3a/3b where indicated).
    When prior trials not metOffer / reviewer action
    Required prior therapy trials not documentedIf required prior trials are not met, offer review for Preferred or Step products listed for the indication (examples include Enbrel, listed adalimumab products, Cimzia, Skyrizi, etc.) using the respective standard prior authorization criteria.
    Counting rules for same-molecule productsTrials of multiple products of the same molecule (e.g., multiple adalimumab products, multiple ustekinumab products) count collectively as ONE trial when assessing step compliance; still offer Preferred/Step alternatives if criteria unmet.
    If criteria not metPreferred / Step options to offer
    Core criteria or Care Value additional conditions not metWhen core or Care Value conditions are not met, reviewer should offer to review for specified Preferred, Step 1, or Step 2a products using the respective standard Inflammatory Conditions prior authorization policy criteria.
    Documentation-directed alternativesExamples of alternatives to offer include Enbrel, adalimumab biosimilars (including those with NDCs starting with 82009), Simlandi, Skyrizi SC, Omvoh SC, Tremfya SC, and others depending on indication.
    Example: Bimzelx / Cosentyx step alternativesPreferred alternatives (examples)
    Bimzelx — Ankylosing Spondylitis; Cosentyx — Ankylosing SpondylitisOffer Enbrel, an adalimumab product (examples include Humira and listed biosimilars/adalimumab-ryvk NDCs starting with 82009), or Taltz as Preferred/Step alternatives when required prior trials are not met.
    Bimzelx / Cosentyx — Plaque Psoriasis and Psoriatic Arthritis examplesOffer Enbrel, adalimumab products, Icotyde, Otezla/Otezla XR, Skyrizi SC, Sotyktu, ustekinumab SC products, Taltz, or Tremfya SC as listed Preferred/Step alternatives per indication.
    If Care Value conditions not metOffer review for
    Care Value additional criteria not satisfied for requested productPolicy requires offering review for specified Preferred, Step 1, or Step 2a products using their respective standard prior authorization criteria rather than approving under the Care Value pathway.
    Examples to offer when Care Value unmetExamples include adalimumab biosimilars (adalimumab-adbm, adalimumab-adaz, adalimumab-ryvk with NDCs starting with 82009), Enbrel, Omvoh SC, Skyrizi SC, Simlandi, Tremfya SC, and others as indicated per condition.
    If core criteria not metReviewer should offer
    Requested product does not meet core indication-specific criteriaReviewer should offer to review for listed Step 1 or Step 2a products (extensive lists provided per indication) using the respective standard PA criteria; documentation of prior trials is required when noted.
    Entyvio SC exampleIf Entyvio SC prior-trial condition not met, offer adalimumab products, Omvoh SC, Skyrizi SC, Stelara/ustekinumab SC products, Tremfya SC, Rinvoq, Simponi SC, Velsipity, or Zymfentra per the standard Entyvio PA criteria.
    When prior therapy trials are lackingOffer review for Step/Preferred lists
    Required prior biologic/step criterion missingOffer review for Step 1, Step 2a, or Preferred Products lists (e.g., Enbrel, multiple adalimumab biosimilars/brands, Simlandi, Otezla, Skyrizi SC, Sotyktu, ustekinumab SC products, Taltz, Tremfya) according to indication-specific lists.
    Documentation requirement reminderWhen offering an alternative, apply the respective standard prior authorization policy criteria; document prior trials where required (a trial of multiple products of same molecule may count as one).
    Prior trial required before approvalIf not met — offer review for
    Prior trial of specified agents required before approvalMany indications require prior trial of agents such as Enbrel, an adalimumab product, Cimzia, infliximab products, or Simponi prior to approving other agents; if trials are not documented, the requestor should be offered review for listed Step 1 or Preferred products.
    Examples of required prior agents by indicationExamples include Enbrel or adalimumab products for RA/PsA; Cimzia, Taltz, or Rinvoq for nr-axSpA; specified TNFi or IL-blockers for other conditions per policy tables.
    Prior TNF or biologic trial per indicationPolicy expectation / alternative review
    Prior trial of specified TNF inhibitor or other biologic required per indicationFor many agents/indications (e.g., Rinvoq, Xeljanz/XR, Cosentyx, Bimzelx), approval requires documented prior trial(s) of a TNF inhibitor (Enbrel, adalimumab products, Cimzia, infliximab products, Simponi) or other specified biologic per the indication.
    If prior trial not documentedOffer review for step/preferred alternatives listed for the indication (e.g., Enbrel, adalimumab biosimilars, Simlandi, Skyrizi SC, Taltz) using the respective standard PA criteria.
    Reference to standard PA policiesInstruction
    Refer to selected standard Prior Authorization Policies for step therapy specificsFor any step therapy requirements or sequencing between agents, review and follow the referenced standard product-specific Prior Authorization Policies (the Care Value policy augments but does not replace those PA policies).

    Continuation / Renewal Criteria

    inv-163: Continuation of therapy (Non-Preferred subcutaneous or oral products requires verification of prior use via claims history or prescriber)

    Continuation of Non‑Preferred subcutaneous or oral products requires verification of prior use; approvals typically for 1 year.

    Continuation verification general: If patient has ≥130 days of prescription claims history, claims must show the Non‑Preferred product was received for the specified period (90 or 120 days) within a 130‑day lookback; OR if 130 days of claims history is unavailable, the prescriber must verify the patient received the Non‑Preferred product for the specified period and via paid claims (no samples/coupons).90 or 120 days within 130‑day lookback

    Approvals for continuation are generally granted for 1 year when verification provided.

    Biosimilar / Same-Molecule Trial Counting and Preferences

    Billing Rule

    Adalimumab‑ryvk NDC prefix noted for preferred listings

    NDCs beginning with 82009 (adalimumab‑ryvk) are identified in policy tables as preferred/Step 1 adalimumab products; when documenting trials of adalimumab products include the product/NDC as applicable.

    Billing Rule

    Multiple adalimumab products count as one trial

    A trial of multiple adalimumab products counts collectively as one prior trial for meeting step requirements; document the adalimumab family trial accordingly rather than counting each brand separately.

    Billing Rule

    Adalimumab products listed as Preferred/Step options (NDC prefix noted)

    Adalimumab products (including adalimumab‑ryvk NDCs starting with 82009) are listed among Preferred or Step options to review when initial criteria are not met; document trials of these specific products as indicated.

    Note
    Billing Rule

    Infliximab (Remicade/biosimilars) may count toward prior‑therapy requirement

    A trial of an infliximab product (e.g., Remicade or biosimilars) may count toward required prior therapy for several indications — include documentation when relying on an infliximab trial.

    Note
    Note
    Note

    Site of Care Considerations

    Note
    Note

    Background and Scope

    Multiple classes of biologic and targeted synthetic therapies are used to manage inflammatory conditions such as rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, Crohn’s disease, and ulcerative colitis. The policy covers a broad set of agents across therapeutic classes and references FDA-labeled indications in appendices and condition-specific prior authorization policies for detailed clinical criteria.

    Definitions and Trial-Counting Rules

    Inflammatory conditions (list of conditions included)
    Included conditionsRheumatoid arthritis (RA), ankylosing spondylitis (AS), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA), plaque psoriasis, Crohn's disease, ulcerative colitis (UC)
    ContextPolicy covers multiple biologic and targeted therapies for listed inflammatory conditions
    CV - Care Value (program designation)
    Program designationCV - Care Value
    RoleCare Value program referenced for step/alternative review pathways
    Trial counting rules (grouping products count as one trial)
    Grouping rule for trialsA trial of more than one adalimumab product counts as ONE Preferred Product for step/trial counting
    Same-family countingTrials of multiple products within the same named product family (e.g., adalimumab, ustekinumab) count collectively as one trial
    DocumentationTrials must be documented (chart notes, prescription claims, receipts) when required
    Counting of same-molecule product trials
    Same-molecule trial countingA trial of multiple products of the same originator molecule (e.g., multiple adalimumab biosimilars) counts as ONE prior product trial
    ExamplesApplies to adalimumab, ustekinumab, tocilizumab groups where listed
    Trial counting rule (multiple products within same family count as one)
    Family-counting ruleA trial of multiple products within the same named product family (adalimumab, ustekinumab, Otezla, Xeljanz, Rinvoq groups) collectively counts as ONE product for prior therapy requirements
    ImplicationReduces requirement when biosimilars/brand variants used sequentially
    Examples of adalimumab products
    Adalimumab examplesHumira, Abrilada, adalimumab-aacf, adalimumab-adaz, adalimumab-adbm, adalimumab-fkjp, adalimumab-aaty, adalimumab-ryvk, Simlandi, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Yuflyma, Yusimry
    NoteMultiple adalimumab products listed can satisfy step requirements; multiple adalimumab trials count as one
    Trial counting rules (multi-formulation counts)
    Multi-formulation countingA trial of either or both formulations of a drug (e.g., Xeljanz tablets and oral solution; Rinvoq and Rinvoq LQ) collectively counts as ONE product trial
    DocumentationDocumentation required where noted for counting toward prior trials
    Trial (definition)
    Definition of 'Trial'A documented attempt of a listed alternative agent; multiple products of the same molecule class count collectively as one product trial when specified
    Acceptable documentationChart notes, prescription claims records, prescription receipts with patient identifiers
    Trial counting rule (grouped product trials)
    Grouped trial countingWhen products are grouped for step purposes (e.g., adalimumab family), multiple products within the group count as a single trial toward step requirements
    ExamplesGroups include adalimumab products, ustekinumab products, Xeljanz/Rinvoq family groupings
    adalimumab product (includes multiple branded/biosimilar products)
    Adalimumab product listIncludes multiple branded and biosimilar adalimumab products (Humira, Abrilada, adalimumab-aacf, adalimumab-adaz, adalimumab-adbm, adalimumab-fkjp, adalimumab-ryvk, Simlandi, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Yuflyma, Yusimry)
    Use in policyThese products are accepted to meet prior-trial requirements where adalimumab is listed
    Adalimumab products (examples listed)
    Adalimumab examples (expanded)Humira; Abrilada; adalimumab-aacf; adalimumab-adaz; adalimumab-adbm; adalimumab-fkjp; adalimumab-aaty; adalimumab-ryvk; Simlandi; Amjevita; Cyltezo; Hadlima; Hulio; Hyrimoz; Idacio; Yuflyma; Yusimry
    Policy noteA trial of multiple adalimumab products counts as one product for prior therapy purposes
    tsDMARDs (definition)
    tsDMARDs termTargeted synthetic disease-modifying antirheumatic drugs (abbreviated as tsDMARDs)
    ContextIncludes oral JAK inhibitors such as Xeljanz, Rinvoq, Olumiant referenced in policy

    Agent-Indication Approval Matrix

    Table 1 presents approved TNF inhibitors by targeted indication; the tabular format implies that some TNFis are not approved for certain indications (represented by '--'). Reviewers should consult Table 1 when determining agent availability for a given condition.

    Several agents in the IL-17/IL-23/IL-12-23 groups are explicitly not approved for specific indications as shown by '--' in the policy tables. Review the IL-17/IL-23 tables for per-agent indication flags before authorizing therapy for those drug classes.

    Revision History

    2026-05-21policy_revisionLatest

    Policy last revised and last reviewed; annual review date set — document updated and published with current criteria and Care Value mappings.

    2026-05-21effective_date

    Policy effective date recorded as 2026-05-21 for the current Inflammatory Conditions Care Value Policy.

    Policy Summary
    Payermedical mutual - ohio
    PolicyInflammatory Conditions Care Value Policy
    Policy CodePolicy N/A
    Change TypeAdministrative — no material clinical changes
    Effective DateMay 21, 2026
    Last ReviewMay 21, 2026
    Next Review DateMay 21, 2026
    Key ActionObtain prior authorization and document required prior therapy trials or claims verification (90–120 days within a 130-day lookback) for continuation approvals.
    SourceLink
    On This Page
    Coverage Criteria by Drug and IndicationCoding and Claims VerificationProvider Required Actions, Documentation, and Denial RisksStep Therapy Tables and Preferred Product PathwaysContinuation / Renewal CriteriaBiosimilar / Same-Molecule Trial Counting and PreferencesSite of Care ConsiderationsBackground and ScopeDefinitions and Trial-Counting RulesAgent-Indication Approval MatrixRevision History

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.